From Medscape Oncology
Medscape Medical News from the:
American Society of Hematology (ASH) 53rd Annual Meeting
December 10 - 13, 2011; San Diego, California
This coverage is not sanctioned by, nor a part of, the American Society of Hematology.
Meeting Highlights at a Glance
- ASH 'Twinning' Strategy Improves Cancer Care in Developing Nations
- ASH Powered Device Hailed as Advance for Bone Marrow Biopsy
- ASH RECOVER II Confirms Benefit of Dabigatran in Treatment of VTE
- ASH Education Gap Identified in the Management of MDS
- ASH New Model Predicts Survival in Treatment-Related MDS
- ASH Use of Genetically Engineered T Cells in B Cell Malignancies
- ASH Less Is More for Rituximab in Low-Burden Follicular Lymphoma
- ASH Vorinostat Shows Activity as Salvage in Multiple Myeloma
- ASH Postthrombotic Syndrome Risk Reduced in DVT
- ASH Less Than 10% of Retrievable IVC Filters Removed
- ASH Genetic Profile in ALL -- Should All Patients Be Screened?
- ASH Transplants With PBSCs Not Better Than Bone Marrow
- ASH Most New Myeloma Patients Respond to Carfilzomib
- ASH Ponatinib Helps Refractory Leukemia in Nearly Half of Patients
- ASH Bortezomib Upfront in Myeloma, Survival Advantage Confirmed
- ASH Obinutuzumab: New Drug to Replace Rituximab?
- ASH Massive Hunt Finds New Mutations That Drive CLL
- ASH Bleeding Risk Scores Provide Mixed Results
- ASH Aspirin a Safe, Low-Cost Option for Preventing Recurrent VTE
- ASH New Insight Into Drug Action in Multiple Myeloma
- ASH Novel Compound Holds Promise in High-Risk CLL
- ASH Long-Term Data Support Chemo Alone in Hodgkin's Lymphoma
- ASH New Lease of Life for Gemtuzumab, Now It Shows Survival Advantage
- ASH First Study Ever of Long-Term Problems After HCT
- ASH What's Hot at ASH 2011?
Medscape Oncology Insights
Pre-Meeting Expert Commentary